BioNxt Solutions Inc.
VANCOUVER, BC / ACCESSWIRE / August 15, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that it has signed a non-binding letter of intent (the "LOI") with German-based international contract research, development, and manufacturing company Gen-Plus GmbH & Co KG ("Gen-Plus"), a part of Conscio Group.
Further to the Master Service Agreement and Cladribine Statement of Work signed by BioNxt and Gen-Plus announced on July 9, 2024, and July 17, 2024, respectively, the LOI recognizes a number of important areas of potential cooperation between the parties, including but not limited to intellectual property and prototype development for new pharmaceutical products, clinical trial planning and batch manufacturing, laboratory, equipment, and office collaboration, business development, and thin film commercial manufacturing. The Company will provide further details on specific cooperation programs as they progress.
Gen-Plus, a part of Conscio Group, has a head office in Munich, Germany, and through the Conscio Group operates within an international network of pharmaceutical service providers with facilities in five countries and over 500 employees. They offer GCP/GLP/GMP/ISO/IEC-certified services and GMP certified manufacturing of clinical trial supplies (Phase I-III) with a specialization in solids, semi-solids, liquids, oral films, and transdermal patches as well as integrated lab analytical services during development & GMP manufacturing, including API characterization, method development, optimization, validation, permeation studies, stabilities studies, etc.
BioNxt is developing a 100% owned and proprietary ODF Cladribine dosage form, directed at the multiple sclerosis ("MS") market. Cladribine tablets are currently approved for use in over 75 countries, including by the United States Food and Drug Administration ("FDA") and the European Medicines Agency ("EMA"), with annual sales in excess of one billion USD. Cladribine tablets are approved for several indications, namely highly active forms of relapsing-remitting MS and certain forms of leukemia. MS represents the largest market segment for the sale of Cladribine with approximately 2.3 million people living with MS worldwide, with the highest prevalence in North America and Europe, noted by Atlas of MS. The global Multiple Sclerosis drug market is expected to top USD 41 billion by 2033 according to Market.us.
The Company has filed Cladribine ODF-related provisional patent applications with three to four patent applications expected to be on file in major international jurisdictions by late 2024 to early 2025 with potential patent protection extending to 2044.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience accelerator focused on next-generation drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical production and evaluation, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.
BioNxt Solutions Inc.
Wolfgang Probst, CEO and Director
Email: info@bionxt.com
Phone: +1 780-818-6422
Cautionary Statement Regarding "Forward-Looking" Information
Some of the statements contained in this news release are forward-looking statements and information within the meaning of applicable securities laws. Forward-looking statements and information can be identified by the use of words such as "expects", "intends", "is expected", "potential", "suggests" or variations of such words or phrases, or statements that certain actions, events or results "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements and information are not historical facts and are subject to a number of risks and uncertainties beyond the Company's control. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this news release. Accordingly, readers should not place undue reliance on forward-looking statements. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements, except as may be required by law.
SOURCE: BioNxt Solutions Inc.
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESSWIRE
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
Addressing Climate Change by Changing Our Food Systems14.1.2025 14:00:00 CET | Press release
WASHINGTON, D.C. / ACCESSWIRE / January 14, 2025 / The year 2024 was the hottest year on record. For the first time the average global temperature rose to 1.6C above preindustrial levels, exceeding the 1.5C vital to preventing accelerating climate change. The effects of climate change are now visible on every continent.Image: www.freepik.com Up to a third of global greenhouse gas production to date can be attributed to animal agriculture and food systems. Yet, most climate change solutions neglect the importance of food systems in climate change mitigation. In the article, ‘Solving Climate Change Requires Changing Our Food Systems,' published in leading scientific journal Oxford Open Climate Change, prominent scientists from around the world propose that the pressing nature of irreversible climate change requires rethinking our food systems. Lead researcher Dr Feigin and her co-authors assert that "we must undertake a global shift to a fundamentally plant-based diet and a gradual globa
The AI Gap: New Survey Reveals Enterprises Are Lagging in the High-Stakes AI Adoption Race14.1.2025 09:00:00 CET | Press release
Nearly 40% of Employees Say Their Organization Is Falling Behind Competitors Due to Slow Adoption NEW YORK, NY / ACCESSWIRE / January 14, 2025 / A striking new survey from Unily uncovers an alarming truth: despite the excitement around AI as a transformative force, many enterprises struggle to adopt the technology in meaningful ways. The result is a growing gap between AI "haves" and "have nots," where enterprises adopting AI tools for their people are making quicker gains than those without. Additionally, employees who are open to using AI tools increasingly want more exposure to them and may even choose employers who are early AI adopters over those who are slower to adapt. The differences between companies and employees that embrace AI and those that don't include a downstream impact on Organizational Velocity. Organizational Velocity is defined as the ability to make sharp pivots, accelerate decision-making, and eliminate operational friction necessary to harness AI's full potentia
Walkbase Launches Game-Changing Millimeter Wave Sensor Solution at NRF's Big Show 202513.1.2025 08:00:00 CET | Press release
New analytics technology set to provide crucial in-store metrics for retail media attribution. NEW YORK CITY, NEW YORK / ACCESSWIRE / January 13, 2025 / STRATACACHE company Walkbase, the leading in-store analytics solutions provider for retailers, today unveils its new millimeter wave sensor technology. The Walkbase Millimeter Wave Sensor Solution provides retailers and premises owners a powerful way to accurately measure in-store customer behavior without collecting or divulging the personally identifying information (PII) of customers.Walkbase Millimeter Wave Sensor Solution NRF attendees learning about Walkbase's Millimeter Wave Sensor Solution The Walkbase Millimeter Wave Sensor Solution will be on display, along with retail solutions from other members of the STRATACACHE family of technology companies including PRN and Scala, at NRF at booth 5213 (level 3). "For retailers looking to track shopper activity in their store, without the risk of collecting unauthorized data, the millim
AML Incubator Launches Compliance Solution for European MSBs and VASPs Facing MiCA Regulatory Challenges10.1.2025 10:45:00 CET | Press release
AML Incubator (AMLI), a leading compliance consultancy, has introduced a new service package to assist European Money Service Businesses (MSBs) and Virtual Asset Service Providers (VASPs) in establishing operations in Canada. The service is designed to help businesses manage complex regulatory challenges arising from the European Union's Markets in Crypto-Assets (MiCA) regulation. VANCOUVER, BC / ACCESSWIRE / January 10, 2025 / The MiCA regulations, part of the EU's digital finance package, imposes strict compliance rules for crypto-asset issuers and service providers. These include licensing, registration, and transparency requirements aimed at improving market stability and investor protection. While MiCA brings greater oversight to the industry, many small and mid-sized MSBs and VASPs are struggling to meet these new demands within the required timelines. As deadlines approach, businesses are exploring alternative jurisdictions that provide clearer regulatory pathways without sacrif
IXOPAY & Riskified Announce Partnership to Boost Fraud Prevention and Enhance Enterprise Payment Orchestration9.1.2025 00:00:00 CET | Press release
The partnership will help ecommerce customers securely expand their businesses by leveraging omnichannel payment orchestration with AI fraud detection LEHI, UT and NEW YORK, NY / ACCESSWIRE / January 9, 2025 / IXOPAY, a leading enterprise payment orchestration platform, and Riskified (NYSE:RSKD), a leader in ecommerce fraud and risk intelligence, today announced a strategic partnership to enhance payment security, reduce fraud challenges and increase payment operation resilience. As global payment ecosystems become more complex, so do the associated risks. IXOPAY and Riskified are teaming up to provide businesses with a seamless, secure and efficient way to enhance their payments orchestration and effectively repel fraud threats. IXOPAY + Riskified IXOPAY and Riskified partnership This partnership combines IXOPAY's payment orchestration, tokenization, and flexible payment optimization capabilities with Riskified's AI-powered fraud and risk intelligence platform. Businesses using this c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom